Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

    ... This study led by Dr. Eric Padron through the MDS Clinical Research Consortium sites showed promising results for a new CMML ... symptoms and may have disease-modifying activity.” Further clinical study is needed to validate the biomarkers of response and ...

    Article last updated 10/17/2018 - 10:10am.

  2. The MDS Clinical Research Consortium

    ... The MDS Clinical Research Consortium (MDS- CRC) is an unprecedented, six-institution ... study was very helpful. A second example is a randomized trial, headed by MD Anderson, of two approved MDS drugs in decreased dose or ...

    Article last updated 10/17/2018 - 9:36am.

  3. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

    ... patients with an IDH2 mutation. This discovery led to a clinical trial involving AG-221 for the treatment of MDS with an IDH2 mutation, ...

    Article last updated 08/30/2018 - 1:32pm.

  4. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... hematopoietic responses were observed in a recent clinical trial using eltrombopag in patients with severe aplastic anemia refractory ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia

    ... purpose of this systematic literature review was to identify clinical trials of MDS and AML that included patient-reported outcome (PRO) ... trials met all criteria (i.e., phase 2 or 3 clinical trial for MDS or AML which included PRO assessment) and were published ...

    Research Article last updated 07/18/2018 - 8:25am.

  6. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... while sparing normal cells. Our purpose is to summarize the clinical activity and safety of intravenous (IV) rigosertib delivered by an ... A multinational pivotal phase 3 randomized clinical trial of rigosertib versus best supportive care for patients with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... the treatment or management of MDS. Of those, six clinical articles of prospective phase 2-3 study design or meta-analyses were ... agents at this time outside the context of a clinical trial . Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Pharmacotherapy of myelodysplastic syndromes.

    ... molecular pathways that account for disease evolution and clinical heterogeneity is expanded, the arsenal of potential drugs that may ... therapy (approved drug or newer agents still in clinical trial ) is likely to be the most beneficial. While there is no single answer ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in ...

    Research Article last updated 07/20/2018 - 5:15pm.